Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Quotient Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Quotient Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Emplicure AB Announce Completion of Phase I PK Study for EMPLI03 with Quotient Sciences
Details : EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 27, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
